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Abstract
Background: A hospital admission offers smokers an opportunity to quit. Smoking cessation counseling provided
in the hospital is effective, but only if it continues for more than one month after discharge. Providing smoking
cessation medication at discharge may add benefit to counseling. A major barrier to translating this research into
clinical practice is sustaining treatment during the transition to outpatient care. An evidence-based, practical,
cost-effective model that facilitates the continuation of tobacco treatment after discharge is needed. This paper
describes the design of a comparative effectiveness trial testing a hospital-initiated intervention against standard
care.
Methods/design: A two-arm randomized controlled trial compares the effectiveness of standard post-discharge
care with a multi-component smoking cessation intervention provided for three months after discharge. Current
smokers admitted to Massachusetts General Hospital who receive bedside smoking cessation counseling, intend to
quit after discharge and are willing to consider smoking cessation medication are eligible. Study participants are
recruited following the hospital counseling visit and randomly assigned to receive Standard Care or Extended Care
after hospital discharge. Standard Care includes a recommendation for a smoking cessation medication and
information about community resources. Extended Care includes up to three months of free FDA-approved
smoking cessation medication and five proactive computerized telephone calls that use interactive voice response
technology to provide tailored motivational messages, offer additional live telephone counseling calls from a
smoking cessation counselor, and facilitate medication refills. Outcomes are assessed at one, three, and six months
after hospital discharge. The primary outcomes are self-reported and validated seven-day point prevalence tobacco
abstinence at six months. Other outcomes include short-term and sustained smoking cessation, post-discharge
utilization of smoking cessation treatment, hospital readmissions and emergency room visits, and program cost per
quit.
Discussion: This study tests a disseminable smoking intervention model for hospitalized smokers. If effective and
widely adopted, it could help to reduce population smoking rates and thereby reduce tobacco-related mortality,
morbidity, and health care costs.
Trial registration: United States Clinical Trials Registry NCT01177176.
Keywords: Smoking cessation, Hospitalization, Pharmacotherapy, Counseling, Randomized clinical trial, Interactive
voice response
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Smoking cessation has health benefits for all smokers,
even those with chronic disease [1-3]. The health care sys-
tem is an important channel for delivering tobacco treat-
ment to smokers. The 2008 US Public Health Service
clinical practice guideline recommends offering treatment,
defined as counseling and medication, to all smokers in
every health care setting, including hospitals [4]. Smoking
status documentation is included as a core measure for
the ‘meaningful use’ of electronic health records in a fed-
eral government program that offers substantial incentive
payments to US physicians and hospitals [5]. This manu-
script describes the protocol for a randomized clinical trial
that compares the effectiveness of two hospital-initiated
tobacco treatment programs that aim to provide post-
discharge cessation treatment.
Each year, nearly four million smokers in the United
States (8.7% of all smokers in the US) spend at least one
night in a hospital [6]. This event provides smokers an op-
portunity to initiate smoking cessation for several reasons.
First, smokers must temporarily abstain from tobacco to
comply with smoke-free hospital policies. Second, illness,
especially if tobacco-related, boosts motivation to quit [7].
Third, hospitalized smokers have intensive contact with
medical personnel who could initiate tobacco treatment.
According to a 2007 Cochrane systematic review of 33 ran-
domized controlled trials of hospital-initiated smoking ces-
sation interventions, hospital-based smoking cessation
interventions are effective, but only if supplemented with
at least one month of follow-up contact after discharge [8].
The review, like the 2008 US Public Health Service Clinical
Practice guideline, recommended that all hospitalized smo-
kers should be offered a smoking counseling intervention
[4]. Subsequent trials support this conclusion [9-11].
Translation of this research into clinical practice was
facilitated in 2004 when tobacco items were included in
National Hospital Quality Measures (NHQM) adopted by
the Joint Commission (JC) and the US federal govern-
ment’s Centers for Medicare and Medicaid Services. These
require hospitals to report publicly how often smokers
with three smoking-related diagnoses (acute myocardial
infarction, congestive heart failure, pneumonia) receive
smoking cessation advice and counseling [12]. These mea-
sures stimulated many hospitals to provide brief smoking
cessation interventions. These measures, while helpful,
were imperfect. They did not apply to all hospitalized
smokers and did not require hospitals to link patients to
tobacco intervention after discharge. Consequently, hospi-
tals that met NHQM standards may not have improved
long-term smoking cessation rates. To address these lim-
itations, the JC has adopted a revised set of tobacco
NHQMs that are currently being reviewed by national sta-
keholders. The revised measures apply to hospitalized
smokers with all diagnoses, require hospitals to document
offers of both medication and counseling to smokers and
document the offer of a plan for post-discharge counseling
and medication [13]. These proposed guidelines have cre-
ated a need for broadly disseminable, post-discharge
smoking cessation interventions.
Sustaining contact and treatment for smokers after
hospitalization provides challenges. First, hospitalized
smokers, motivated by a serious medical event and per-
haps attributing their nicotine withdrawal symptoms to
the discomfort of hospitalization, may not anticipate their
difficulty staying quit when they return home. Despite
high levels of motivation to quit reported in hospitalized
smokers [14,15] at least half of smokers, resume smoking
within three days of hospital discharge [16]. Second, sus-
taining treatment regimens from inpatient and outpatient
care settings is a challenge for the management of chronic
diseases, including tobacco dependence [17-19]. Strategies
to avoid gaps in care are needed to prevent relapse after
discharge. Third, while hospital clinicians can provide pre-
scriptions for smoking cessation medications, many of
these medications are not covered by insurance, leaving
barriers of cost and convenience which preclude patients
from filling them [20]. Information about the cost effect-
iveness of post-discharge smoking cessation interven-
tions in terms of reductions in longer-term healthcare
spending might encourage insurers to expand coverage.
Fourth, while hospital staff can provide information
about available community smoking cessation resources
for post-discharge care, few patients access these
resources if the referral is done passively [21]. This may
be due to barriers of cost, convenience, or lack of in-
strumental support to coordinate services (for example,
social workers, nurses).
The current study
The current study is a randomized controlled effective-
ness trial, the Helping Hospital-initiated Assistance for
Nicotine Dependence (Helping HAND) Trial, which
compares an Extended Care Model designed to address
these barriers and facilitate the delivery of the two com-
ponents of effective tobacco treatment (smoking cessa-
tion medication and counseling support) after hospital
discharge against Standard Care. This paper describes
the protocol for this clinical trial.
To sustain counseling support, the model incorporates
interactive voice response (IVR) technology to triage
patients to post-discharge treatment resources. IVR is a
telephone technology in which a computer detects voice
and touch tones and responds to callers with pre-recorded
audio. In the hospital setting, IVR systems are used to as-
sess patients for adverse outcomes after outpatient surgery
[22-25]. A‘call-out’ IVR system, in which a computer initi-
ates the call, could reduce the cost of contacting smokers
by substituting a computer for a human caller, making
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IVR can serve a number of clinical functions including: (1)
providing rapid telephone contact after discharge (at a
time when patients are at higher risk for relapse), (2) pro-
viding motivational messages and information to encour-
age patients to continue cessation efforts and medication
use, (3) enhancing counseling efficiency by identifying
smokers likely to benefit from it, and (4) facilitating suc-
cessful connection to counseling services.
IVR technology has been used to sustain contact with
smokers after hospital admission. The feasibility of an IVR
system designed for smokers with coronary heart disease
(CHD) called the Ottawa Model was demonstrated in an
uncontrolled study [26]. A small pilot trial assessing the
model produced a non-significant increase in one-year
point prevalence quit rates over usual care, from 35% to
46%, but the trial was underpowered [27]. The Ottawa
Model was subsequently expanded for use with all hospi-
talized smokers and, in a non-randomized pre-post study
it was successfully implemented as a comprehensive pro-
gram for smokers who were admitted to nine general hos-
pitals in Ontario, Canada [28]. Six-month continuous quit
rates increased from 18% before to 29% after implementa-
tion. That study assessed the combined effect of both the
inpatient and outpatient components of the model and
therefore was not designed to test the independent contri-
bution of the post-discharge component.
The second component of the Extended Care Model
aims to increase adherence to smoking cessation medi-
cation after discharge. Patients are given a free one-
month supply of their choice of smoking cessation medi-
cation and offered two free refills. This obviates filling a
prescription or paying for medications not covered by
health insurance. The 2008 Clinical Practice Guideline
demonstrated that using FDA-approved smoking cessa-
tion medication (nicotine replacement therapy, bupro-
pion and varenicline) can double to triple the odds of
successful cessation [4]. Providing free medication at dis-
charge, rather than medication recommendations or pre-
scriptions, removes barriers of cost and convenience to
increase use [29-31]. Primary care clinics and state
tobacco control programs that have provided free medi-
cation with few barriers to access have observed
increased smokers’ utilization of medication when trying
to quit [32-37].
The aim of the Helping HAND trial is to compare the
effectiveness of the Extended Care program with Standard
Care for increasing smoking cessation rates at six months
after hospital discharge. The Extended Care program pro-
vides free smoking cessation medication and proactive
IVR calls for three months after hospital discharge. The
calls assess smoking status, triage patients to smoking ces-
sation resources and facilitate the provision of up to a
three-month supply of FDA-approved smoking cessation
medication. We hypothesize that Extended Care will in-
crease rates of smoking cessation compared to standard
care and will also increase the use of smoking cessation
resources (counseling and medication) after discharge. An
exploratory aim is to determine the cost-effectiveness of
the program, compared to Standard Care, in terms of re-
duction of healthcare costs due to reduced utilization of
hospital-based acute care in the Extended Care group
(hospital readmissions and emergency room visits).
Methods/design
Design
The Helping HAND study is a two-arm randomized
controlled trial of a post-discharge treatment program
for hospitalized smokers (Figure 1). The arms are Stand-
ard Care and Extended Care. Participants are followed
for six months after hospital discharge. The study site is
Massachusetts General Hospital (MGH), a 900-bed
urban teaching hospital in Boston, MA, which admitted
51,024 patients in 2009. The goal is to recruit 330 hospi-
talized smokers. Recruitment began in July 2010. The
study is approved by the Partners Health System Institu-
tional Review Board and is registered with the United
States National Institute of Health Clinical Trials Regis-
try (NCT01177176).
Participants
Inclusion criteria
MGH inpatients are eligible for the study if they:
 Are an adult (≥18 years old).
 Are a current daily smoker (smoked≥1 cigarette/
day in the past month when smoking in their usual
pattern).
 Plan to sustain or initiate a quit attempt after
hospital discharge, assessed by asking the smoker to
endorse one of four options (‘I will stay quit’,‘I will
try to quit’,‘I don’t know if I’m going to quit’,‘Id o
not plan to quit’). Only those smokers who endorse
the first two responses are eligible for study
enrollment.
 Have received smoking cessation counseling (for
more than five minutes) and post-discharge smoking
cessation medication recommendations from the
MGH Tobacco Treatment Service staff.
 Are being discharged to home or, if discharged to a
rehabilitation facility, have a mobile telephone on
which they can receive the IVR calls.
Exclusion criteria
Patients are excluded if they:
 Have cognitive impairment that precludes providing
consent or participating in the intervention (for
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Figure 1 Helping HAND study diagram.
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or other altered mental status).
 Have a communication barrier precluding use of
interactive voice response calls (for example, speech
or hearing impairment, unable to speak English).
 Are pregnant, are too sick to receive the
intervention or have limited life expectancy (for
example, metastatic cancer, on hospice or palliative
care; admitted from a nursing home).
 Have an admitting diagnosis directly due to active
substance abuse (for example, overdose, detox) or
have a past year history of substance use disorder
diagnosis (excluding marijuana, alcohol and
tobacco).
 Are unwilling to accept smoking cessation
medications to take home.
Procedure
MGH inpatient protocol for smokers
The smoking status of all patients admitted to MGH is
identified on admission and documented in the hospital’s
computerized order entry system. This system includes a
drop-down menu with a check box for ordering nicotine
patches. All FDA-approved medications, including the
nicotine patch, gum, lozenge, and inhaler, bupropion,
and varenicline, are on the hospital formulary. An
internally-developed four-page pamphlet, A Guide for
Hospital Patients Who Smoke, is put in the admission
packet at every new patient’s bedside. It outlines reasons
why a hospital admission is a good time to quit, educates
patients about nicotine withdrawal symptoms and how
to manage them, and provides contact information for
community smoking cessation resources, including the
state quitline.
The computerized order entry system automatically
delivers to the MGH Tobacco Treatment Service (TTS)
an electronic list of all admitted patients identified as
having smoked in the past year. A TTS staff member (a
certified Tobacco Treatment Specialist) [38] attempts to
visit each smoker at the bedside, usually on the day after
admission. The counselor follows a protocol to maxi-
mize patient comfort by ensuring adequate treatment of
nicotine withdrawal symptoms in the hospital, provides
advice to quit, and assesses a smoker’s readiness to quit
after discharge. For smokers who are not ready to quit,
these visits are brief, typically lasting fewer than five
minutes, and these individuals are not eligible for study
recruitment. For smokers considering tobacco abstin-
ence after hospital discharge, the TTS counselor con-
ducts a standard assessment and helps the smoker to
make a quit plan. This includes a recommended smok-
ing cessation medication and information about commu-
nity smoking cessation counseling. The counselor’s
medication recommendation is based on patient medical
history, prior experience with cessation medications, and
patient preference. It avoids medications contraindicated
for the participants’ medical condition or those that have
resulted in past adverse reactions. Counseling visits last
a median of 20 minutes.
Study recruitment
The TTS counselor screens inpatients who were coun-
seled (operationally defined as receiving more than five
minutes of contact) for inclusion criteria, using a stand-
ard form. Patients who meet these criteria are briefly
introduced to the study and are referred to research
staff, who assess for exclusion criteria using chart review,
patient interview, and, as necessary, discussions with the
patients’ care team. Eligible patients are provided
detailed study information. If willing to participate, they
provide written informed consent and complete a ten-
minute interview to collect baseline measures and
detailed contact information.
Assignment to treatment group
Participants are randomly assigned at the bedside to either
Standard Care or Extended Care by research staff, in a 1:1
fashion in permuted blocks of eight randomization num-
bers. Randomization is stratified by two expected pre-
dictors of smoking cessation success, daily cigarette
consumption in the month prior to admission (< 10 ver-
sus>=10 cigarettes per day) and admitting service (car-
diac versus other). Randomization is concealed by placing
information about randomization condition into sealed
envelopes. When a participant is randomized, the research
staff member opens the next envelope corresponding to
the participant’s randomization stratum, shares it with the
participant, and initiates the assigned intervention. Re-
search staff do not track the beginning and end of
randomization blocks. Thus, neither the participant nor
the research staff know participants’ randomization group
before participants are enrolled.
Outcome assessment
Participants are contacted by study staff via telephone at
one, three and six months after discharge to collect out-
come measures, including: smoking status, use of smok-
ing cessation medication and counseling, hospital
readmissions, emergency room visits and, in the inter-
vention group, satisfaction with the IVR system. A $20
gift card is provided for each completed follow-up call.
A reminder letter is sent one month before the six-
month call. At one month, the call window begins three
days before the target date and ends two weeks after the
target date. At three and six months, the call windows
begin two weeks before the target date and end four
weeks after the target date. Study staff make up to ten
call attempts to the participant, using all available phone
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at several different times of day, with more calls made
during the participants’ self-reported best time to call. If
participants cannot be reached, study staff call partici-
pants’ alternative contacts (people whom the participants
reported would know how to reach them) to verify parti-
cipants’ contact information. A letter is also sent to the
participants indicating that we are trying to reach them
and asking them to call the study line.
Validation of tobacco abstinence
Self-reported tobacco abstinence is validated in two ways
at three and six month follow-ups: biochemically, and by
asking a ‘proxy’ (a friend or family member of the par-
ticipant) to confirm smoking status. We biochemically
validate abstinence status for all participants reporting
non-smoking, but we also contact proxies for all partici-
pants. First, participants who self-report being quit are
asked to mail a saliva sample for assay of cotinine, a
nicotine metabolite. Because nicotine replacement ther-
apy (NRT) use produces detectable cotinine, the valid-
ation criterion for a patient reporting current NRT use
is an expired-air carbon monoxide measurement of≤9
ppm, obtained at a hospital or home visit [39]. Partici-
pants are paid $50 for providing a sample for biochem-
ical validation. We also validate smoking status by proxy
report. At the baseline survey participants are asked to
give the names of three people who would know
whether they were smoking to serve as proxies. At three
and six months, after the participant’s self-report is
obtained, we call the participant’s proxy to obtain con-
firmation of the participant’s current smoking status.
This is done for participants who report smoking as well
as those reporting being abstinent. To ensure that prox-
ies are good reporters of smoking status, we also ask
when they last had contact with the participant.
Interventions
Standard care
Participants receive the MGH inpatient protocol during
the hospital stay. As described above, the smoking
counselor provides information to smokers about post-
discharge counseling resources and makes a specific
recommendation for post-discharge medication. The
counselor also puts these recommendations in a written
consultation note in the hospital chart.
Extended care
Participants in the Extended Care group receive stand-
ard care for smoking cessation plus a two-component
intervention which consists of: (1) a one month supply
of smoking cessation pharmacotherapy (that can be
refilled twice over the three month intervention period)
and (2) five calls from the IVR system (plus opportun-
ities to speak with a live counselor).
Pharmacotherapy A free one-month supply of the
counselor-recommended FDA-approved smoking cessa-
tion medication is prescribed by the hospital physician,
filled in the hospital pharmacy and delivered to the patient
by study staff prior to discharge, along with information
on proper medication use, side effects, and instructions
on how to obtain two free refills using the IVR system
described below. Pharmacotherapy choices include single
agents (NRT, bupropion, or varenicline) or combination
treatments (nicotine patch+gum or lozenge, bupropion+
nicotine patch, gum, or lozenge). Information about the
discharge medication is sent to the patient’s primary care
provider, whom the patient is told to contact in case of ad-
verse events.
IVR The IVR system (administered by TelAsk Tech-
nologies, Ottawa, Canada) provides automated telephone
calls at 2, 14, 30, 60 and 90 days after discharge. Dis-
charge dates and participant phone numbers are trans-
ferred to the IVR vendor by the study team via secure
FTP. The IVR system makes up to eight attempts to
reach participants for each scheduled call, beginning on
the scheduled call day and proceeding with two calls
p e rd a yf o rf o u rd a y so ru n t i lt h ec a l li sc o m p l e t e d .C a l l s
are scheduled at participants’ preferred times. The
current system is adapted from a previous IVR system
that was tested in a pilot trial and demonstrated to be
feasible [40].
The IVR calls have four goals: (1) assessing smoking
status and medication use, (2) providing motivational
messages tailored to smoking and medication use status,
(3) triaging participants to smoking cessation resources,
and (4) offering refills of the study medication. Each IVR
call assesses current smoking status and intention to
quit, current use of smoking cessation medication, medi-
cation side effects, and patient’s desire for telephone
counseling support. This information is used to tailor
motivational messages that encourage participants to
use smoking cessation medications and to speak with
counselors when needed (for example, ‘Using medicine
doubles your chance of quitting smoking for good. We
recommend that you talk with our tobacco counselor
about how to get started on your medicine’). Participants
are prompted by the IVR system to renew smoking ces-
sation medications, to change administration schedules
when necessary (that is, tapering nicotine replacement
therapy), and to speak to smoking cessation counselors
when they are having difficulties with medication or with
staying quit. While participants can request a return call
from a counselor at the end of any IVR call, the system
recommends that the participant request a return call if
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ger the system to recommend a return call from a live
counselor include: (1) participants who do not start
pharmacotherapy after discharge or stop pharmacother-
apy before the end of the 90-day course; (2) participants
who resume smoking after discharge but still want to
quit; (3) participants who are quit but have a low level of
confidence in their ability to stay quit; (4) participants
reporting medication side effects (see Figure 2 for sam-
ple IVR call). The IVR system prompts the participant to
request a refill at only two calls; however, participants
may request refills during any return call from the study
counselor.
IVR return calls The smoking cessation counseling is
protocolized, uses a motivational interviewing style [7]
and focuses on providing behavioral techniques to help
participants stay quit or re-start quit attempts and increas-
ing adherence to smoking cessation medication. Behav-
ioral counseling modules include managing withdrawal
symptoms, craving, mood and stress, and accessing com-
munity resources for smoking cessation treatment. Medi-
cation management modules focus on medication
instructions, managing side effects, and deciding when to
stop medicine or change dose. Participants requesting
refills are evaluated for side effects and all medication
questions are answered.
Measures
Baseline
Demographics are collected by chart review (gender, age,
health insurance) and in the baseline survey (race/ethnicity,
education, employment status, marital/partner status).
Smoking history is collected during the hospital
tobacco counseling visit and includes: cigarettes per day
in the month prior to admission, use of non-cigarette
tobacco products, age of smoking initiation, number of
years smoking, quit history (ever tried to quit, length of
longest quit), previous use of tobacco treatment (coun-
seling, pharmacotherapy), living with a smoker, home
smoking policy, in-hospital rating of cigarette craving,
perceived importance of quitting, perceived confidence
in ability to quit (ten point Likert scales), and intention
to quit upon discharge from the hospital (‘I will stay
quit’ or ‘I will try to quit’).
Nicotine dependence is measured using the Fager-
ström Test of Nicotine Dependence (FTND) [41]. The
FTND comprises six items with scores ranging from 0
to 10; higher scores indicate greater dependence.
Depression Depressed mood is measured using the
eight-item Center for Epidemiological Studies Depression
Scale [42] at baseline. Participants rate depressive symp-
toms over the past week on a four-point Likert scale.
Scores range from 0–24, with higher scores indicating
greater depression.
Alcohol use is assessed at baseline with the three-item
Alcohol Use Disorders Identification Test – Consump-
tion (AUDIT-C), which assesses quantity and frequency
of alcohol use and frequency of binge-drinking episodes
and generates a tailored risk rating [43].
Hospital admission characteristics Length of hospital
stay, primary and secondary hospital discharge diagno-
ses, hospital service, and patient’s disposition after dis-
charge (home or rehabilitation facility) will be obtained
from hospital records.
Follow-up (one, three and six months)
Smoking status The primary outcome is validated seven-
day point prevalence abstinence from tobacco at six
months after discharge. The principal secondary outcome
measure is self-reported seven-day point prevalence ab-
stinence at six months after discharge. Self-reported
tobacco abstinence is defined as answering no to two
questions: ‘In the past seven days have you smoked a
cigarette, even a puff?’; ‘In the past seven days, have you
used any tobacco product other than cigarettes such as
cigars, pipes, snuff or chew?’ Patients who report tobacco
abstinence are asked to provide biochemical and proxy
validation (described above) for the primary outcome
measure. Subjects who self-report smoking or whose coti-
nine or CO measures exceed the cut-offs (10 ng/ml for
cotinine; 9 ppm for CO) are counted as smokers. Subjects
with missing data (who are lost to follow-up or who self-
report nonsmoking but do not provide a sufficient saliva
sample, CO measurement, or proxy validation) are consid-
ered smokers for the primary analysis, but in secondary
analyses, outcome will be imputed via statistical modeling.
Other secondary outcome measures of smoking status
include: (1) self-reported seven-day point-prevalence
tobacco abstinence at one and three months; (2) con-
tinuous abstinence from cigarettes and other tobacco
(‘Since you left the hospital, have you smoked a cigarette,
even a puff?’; ‘Since you left the hospital, have you used
any tobacco product other than cigarettes such as cigars,
pipes, snuff or chew?’), (3) prolonged abstinence, defined
as not using tobacco at one, three and six month follow-
up points; (4) duration of tobacco abstinence after dis-
charge; (5) proportion of participants who make a 24-
hour quit attempt after discharge (‘Since you left the
hospital have you not smoked for 24 hours because you
were trying to quit?’).
Stage of change/confidence We assessed confidence
(‘On a scale of one to ten, how confident are you that
you will stay quit for the next year, with one being not at
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Figure 2 Sample Interactive Voice Response call design.
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those who have quit or who have a specific plan to quit
in the next 30 days. For those who are still smoking, we
assess stage of change by asking if participants have ‘ser-
ious plans to quit in the next six months’ and ‘a specific
plan to quit in the next 30 days’ [44].
Inpatient experience with tobacco abstinence and
smoking cessation medication use At the one-month
follow-up (or the first follow-up completed), participants
rate the difficulty that they had maintaining abstinence
in the hospital (‘How hard was it not to smoke while
you were in the hospital?’), using a four point Likert
scale (not at all-very). Smoking while in the hospital is
assessed (‘Did you smoke a cigarette, even a puff, during
your stay in the hospital?’). Finally, we assess use of
smoking cessation medications during hospitalization in-
cluding use of the nicotine patch, nicotine gum, nicotine
lozenge, nicotine inhaler, bupropion or varenicline.
Smoking cessation medication use/adherence We as-
sess post-discharge use of any of the FDA-approved
smoking cessation medications including nicotine re-
placement (patch, gum, lozenge, inhaler, nasal spray),
bupropion or varenicline. For those medications that are
used we assess dose, frequency, duration of use and rea-
son for termination. We also assess the source of these
medicines (for example, provided by the study, obtained
by prescription or purchased over the counter).
Post-discharge smoking cessation counseling use Par-
ticipants are asked whether they have spoken to a
counselor or health care provider about their smoking
since hospital discharge. Those who have spoken to a
provider about their smoking are asked to whom they
spoke (study counselor, state quitline, doctor, nurse,
community counselor), how many times they received
smoking cessation counseling, and the main topics
discussed.
Post-discharge utilization of acute health care services
We assess emergency room visits and hospital readmis-
sions during the six months after the discharge from the
hospitalization at which enrollment occurred. Emergency
room visits and hospitalizations are assessed two ways.
First, an electronic medical record tracking system auto-
matically notifies study staff whenever any participant is
admitted to any emergency room or hospital in the Part-
ners HealthCare System, the integrated health care deliv-
ery system to which MGH belongs. Second, participants
are asked at each follow-up survey whether they have been
to an emergency room or been hospitalized since their
index hospital discharge. Questions are adapted from the
2008 National Health Interview Survey (‘Were you seen in
an emergency room but not admitted to the hospital dur-
ing the six months after you left MGH on (discharge
date)?’; ‘Were you hospitalized anywhere overnight during
the six months after you left MGH on (discharge date)?
Do not include an overnight stay in the emergency
room.’). These allow us to identify a hospitalization or
emergency room visit made by a participant to a hospital
outside Partners system. We request discharge summaries
for admissions to hospitals outside Partners HealthCare
System. Measures for health care utilization after dis-
charge consist of: (1) number of hospital readmissions; (2)
number of hospital days; (3) number of emergency room
visits; (4) total number of hospitalizations and emergency
room visits.
Satisfaction with IVR system Participants in the
Extended Care group who have answered at least one
IVR call are asked three questions about satisfaction
with the IVR (‘How helpful was it to get phone calls to
check in about your smoking after you left the hospital?’
[very helpful-not at all helpful]; ‘If a friend or family
member who smokes and wanted to stop were hospita-
lized, would you recommend that they be followed by an
automated telephone support system to help them stop
smoking?’ [strongly recommend-strongly not recom-
mend]; and an open-ended question asking what was
and was not helpful about the IVR).
Quality assurance
All referrals to the inpatient TTS and their disposition
are recorded and monitored. Counselor screening forms
and referrals are monitored to ensure that appropriate
patients are being referred. Screening and recruitment
reports are monitored weekly. Research staff meets with
study counselors monthly to discuss any problems. Re-
ceipt of medication prior to discharge is tracked for each
participant, and mailing medication used as the back-up
strategy. The IVR web interface and IVR call completion
rates are monitored weekly. All counseling sessions are
recorded and 10% are reviewed for protocol adherence
by a supervisor, a tobacco treatment counselor who is
distinct from the one who delivered the treatment. Com-
pletion rates of follow-up assessments are reviewed
weekly.
Data analysis
Sample size and power calculations
We estimate that the primary outcome, verified seven-
day tobacco abstinence rate at six-month follow-up, will
be 20% among the Standard Care group and 35% among
the Extended Care group. With a sample size of 165 per
group, the study has 83% power to detect this difference
with a 0.05 two-sided significance level. The estimate of
the Standard Care cessation rate was extrapolated from
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from the MGH TTS. The rate ratio (35/20=1.75) was
based on results of a recent meta-analysis [8] but
increased to reflect expected improvement due to pro-
ject innovations.
Comparison of smoking status outcomes
The primary analysis will be done using the intention-
to-treat perspective, regardless of whether patients in
the Extended Care group took medications or partici-
pated in the IVR intervention. In the primary analysis,
patients who are not reached for follow-up or who have
not validated smoking cessation (either a saliva coti-
nine<10 ng/ml, CO<9 ppm or proxy verification) will
be considered to be smoking. A secondary analysis will
use multiple imputation techniques for missing bio-
chemical verification values. Cross-sectional analyses will
be conducted for outcomes assessed at one, three and
six months after discharge.
Chi-square tests will be used to compare smoking ces-
sation rates between the Extended Care group and the
Standard Care group at each time point. Logistic regres-
sion analysis will be used to compare the two groups
with age, sex, discharge diagnosis (cardiac versus other)
and cigarettes smoked per day as the additional factors
in the model. A longitudinal analysis using Generalized
Estimating Equations (GEE) techniques will be used to
assess the overall impact including data from all follow-
up times while accounting for similarity in patient data
across multiple assessment points. In a secondary ana-
lysis, we will use multiple imputation techniques for
missing biochemical or proxy validation data. Self-
reported seven-day point prevalence abstinence is the
principal secondary endpoint.
Other smoking status outcomes compared between
groups will be: (1) continuous abstinence; (2) pro-
longed abstinence (defined as quit at one, three and six
months); (3) time to slip or relapse (first cigarette
smoked after discharge); and (4) making a quit attempt
(defined as intentionally not smoking for≥24 hours)
after discharge. Continuous and sustained abstinence
and whether or not the participant made a quit attempt
will be assessed using chi-square tests and logistic re-
gression. Time to relapse will be assessed using sur-
vival analysis with Cox proportional hazards models. A
secondary hypothesis is that participants in the
Extended Care group will have higher rates of using
smoking cessation pharmacotherapy and counseling
Table 1 Helping HAND trial measures by assessment time point
Measure Baseline Outcomes
1 Month 3 Month 6 Month
Demographics X
Smoking History X
Nicotine dependence (FTND) X
Depression symptoms (CES-D) X
Alcohol use (AUDIT-C) X
Smoking status X X X X
Non-cigarette tobacco use X X X X
Biochemical validation
a XX
Proxy validation
b XX
Smoking during index hospital stay X
Readiness to quit smoking X
Confidence in ability to quit or stay quit X
Smoking cessation medication used X X X
Smoking cessation counseling used X X X
Healthcare utilization
Hospital admission X X X
Emergency room visit X X X
Satisfaction with IVR
c X
aRequested from self-reported nonsmokers only. Saliva cotinine requested by mail, unless participant is using nicotine replacement, in which case a visit for
measurement of expired air CO is requested.
bObtained from all participants, regardless of self-reported smoking status at outcome assessment.
cIf the participant
was not reached for the one-month follow-up, these questions were asked at the first follow-up for which the participant was reached. AUDIT-C, Alcohol Use
Disorders Identification Test – Consumption; CES-D, Center for Epidemiological Studies 8-item Depression Scale; FTND, Fagerström Test for Nicotine Dependence;
IVR, Interactive Voice Response.
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and counseling will be assessed using chi-square tests.
Utilization of acute health care services
We hypothesize that the Extended Care group will have
a lower rate of acute health care utilization than the
Standard Care group in the six months after hospital
discharge. Logistic regression will be used to determine
whether the Standard Care group was more likely to
have any hospital admissions or emergency room visits
and Poisson regression models will be used to determine
whether the Standard Care group had a higher number
of admissions or hospital days [45].
Cost effectiveness
Cost-effectiveness analyses will be assessed by cost
per quit as the main outcome to ensure maximum
comparability with other published studies [46,47].
The incremental costs per quit are estimated as fol-
lows: (Total costs of Extended Care - Total costs for
Standard Care)/(Total successful quits at six months
for Extended Care - Total successful quits at six
months for Standard Care). The major costs tracked
in the study are described in Table 2. In the inter-
vention arm, these include Tobacco Counselor time
(based on hourly wage), the cost of the IVR service,
the cost of providing a free pharmacotherapy to par-
ticipants after discharge, and the cost of any add-
itional counseling or pharmacotherapy used by
participants. The major costs in the Standard Care
arm that require tracking are the use of post-discharge
counseling or pharmacotherapy. For both study arms
we will track the portion of counseling and therapy
costs (exclusive of the 90-day supply of pharmacother-
apy specific to the intervention) paid for by participants
out of pocket versus by insurance. Prospective collec-
tion of cost information (for example counselor time)
will maximize the accuracy of our data.
Discussion
Hospital admission is a ‘teachable moment’. Strong evi-
dence supports the efficacy of smoking interventions for
hospitalized patients, but only if smoking treatment is
sustained for longer than one month after discharge. For
dissemination into practice, the critical challenge is iden-
tifying a strategy to link hospitalized smokers to tobacco
treatment after discharge. Our study compares two strat-
egies to accomplish this goal.
If the intervention is effective, its sustainability will
be an important consideration. An IVR system is po-
tentially sustainable because it has a low per-user
cost due to automation of calls that allows counsel-
ing to be targeted more efficiently than if a live
caller were calling every patient. However, partici-
pants who request counseling at the IVR contact
need to be contacted by a live counselor at a separ-
ate time. The choice of who would make and pay for
these calls would affect its sustainability. One strat-
egy to limit costs to the hospital and enhance disse-
minability would be a system in which participants
who request a counseling call are automatically and
seamlessly transferred from the IVR system to the
state telephone quitline instead of relying on hospital
counseling resources.
We hypothesize that providing medication in hand
at discharge at no cost to the patient is a critical
component of the intervention. This study tests the
feasibility and impact of the strategy. If successful,
providing free medication will be an added cost in the
dissemination of the program because nonprescription
nicotine replacement is not covered by many health
insurance plans. However, new models of health care
organization with different reimbursement strategies,
such as accountable care organizations, are being
implemented [49]. These organizations may be more
amenable to considering coverage of NRT after hos-
pital discharge, especially if this intervention is shown
to reduce hospital readmissions or subsequent emer-
gency room use.
Table 2 Cost data collection domains
Resource Description Source of resource use data Source of cost data
Tobacco counselor time
– pre-discharge
Initial assessment (Counselor chart review and
meeting with the patient to determine a quit plan),
medication recommendations, and counseling
Study records Human resources data
Tobacco counselor time
– post-discharge
Medication and cessation support, time
spent trying to reach subjects
Study records,
survey responses
Human resources
data, published
reports and datasets
IVR service Automated telephone outreach to smokers. Study records Study records
Smoking cessation
medications
FDA-approved smoking cessation medications
provided to patients at discharge from the hospital and
subsequent refills (includes mailing costs)
Study records Hospital billing data
Smoking cessation medications obtained
by patients after discharge
Survey responses Red Book 2010 [48]
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whether to target all hospitalized smokers or only
those who state an intention to quit smoking after
discharge. We chose the latter approach, reasoning
that less motivated smokers were unlikely to use the
interventions, that the intervention would be most
cost-effective for those intending to quit, and therefore
am o r et a r g e t e di n t e r v e n t i o nw o u l dh a v et h eb e s t
chance of being adopted into clinical practice. This
will likely increase cessation rates in both groups.
While we believe that smokers planning to quit are
the patients most likely to accept and benefit from
our intervention, if it is successful, future studies
could implement the intervention more broadly.
Our study design assesses the combined effect of
an intervention package consisting of two compo-
nents (IVR+medication provision) compared to
standard care (counseling information and medica-
tion recommendation). This design does not permit
us to determine the relative contribution of the indi-
vidual intervention components (IVR/counseling or
medication) to any effect that we might find. While
a factorial design would allow us to distinguish the
independent effects of counseling and medication,
t h i sw o u l dr e q u i r eal a r g e rs a m p l es i z e .I ft h ec o m -
bined intervention proves effective, subsequent trials
could examine the relative contributions of the coun-
seling support and medication.
In summary, an evidence-based, cost-effective inter-
vention model that is readily adoptable by US hospi-
tals is needed in order to realize the potential impact
of hospital-initiated smoking interventions and to
meet new hospital quality measures under review.
This trial is testing an intervention designed to meet
this need. A cost-effective smoking intervention model
for hospitalized smokers could, if widely adopted, help
to reduce population smoking rates and thereby con-
tribute to reducing tobacco-related mortality, morbid-
ity, and health care costs.
Trial status
Recruitment was completed in April 2012. Follow-up data
collection will be completed in November 2012.
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